simAbs
SIMABS develops and operates a continuous bioprocessing platform for small-volume, high-productivity manufacturing of therapeutic biologics. Services include cell-line development, upstream and downstream process optimization, analytical and formulation development, GMP manufacturing and technology transfer. The company emphasizes reduced footprint, cost-efficiency, inline quality control (PAT) and digital process control to accelerate time-to-market.
Industries
Nr. of Employees
small (1-50)
Products
Integrated continuous antibody production platform
A continuous manufacturing platform combining multiple unit operations (upstream and downstream) into an integrated flow designed for high productivity, reduced cleanroom footprint and inline quality control to accelerate development and manufacturing of antibodies and related biologics.
Integrated continuous antibody production platform
A continuous manufacturing platform combining multiple unit operations (upstream and downstream) into an integrated flow designed for high productivity, reduced cleanroom footprint and inline quality control to accelerate development and manufacturing of antibodies and related biologics.
Services
Process Development
Development of continuous upstream and downstream processes for recombinant proteins with focus on speed, cost-effectiveness and consistent quality across flexible production scales.
Process Development
Development of continuous upstream and downstream processes for recombinant proteins with focus on speed, cost-effectiveness and consistent quality across flexible production scales.
Expertise Areas
- Continuous biomanufacturing
- Cell line engineering
- Upstream and downstream process development
- Analytical development and QC
Key Technologies
- Continuous bioprocessing (perfusion/steady-state operation)
- CHO-based recombinant expression
- Cell line development and master cell banks
- Chromatography and multi-column purification methods